Adagene Inc
NASDAQ:ADAG

Watchlist Manager
Adagene Inc Logo
Adagene Inc
NASDAQ:ADAG
Watchlist
Price: 1.764 USD -2.54%
Market Cap: 83.1m USD

Operating Margin
Adagene Inc

-32 284.9%
Current
-10 503%
Average
-3.9%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-32 284.9%
=
Operating Profit
-33.3m
/
Revenue
103.2k

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
CN
Adagene Inc
NASDAQ:ADAG
83.1m USD
-32 285%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
393.4B USD
33%
US
Amgen Inc
NASDAQ:AMGN
171.4B USD
34%
US
Gilead Sciences Inc
NASDAQ:GILD
153.3B USD
39%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
113.9B USD
39%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78B USD
28%
AU
CSL Ltd
ASX:CSL
89.1B AUD
26%
NL
argenx SE
XBRU:ARGX
45.8B EUR
22%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
53B USD
8%
No Stocks Found

Adagene Inc
Glance View

Market Cap
83.1m USD
Industry
Biotechnology

Adagene, Inc. engages in the discovery and development of novel antibody-based cancer immunotherapies. The company is headquartered in Suzhou, Jiangsu. The company went IPO on 2021-02-09. The firm is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.

ADAG Intrinsic Value
1.052 USD
Overvaluation 40%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-32 284.9%
=
Operating Profit
-33.3m
/
Revenue
103.2k
What is the Operating Margin of Adagene Inc?

Based on Adagene Inc's most recent financial statements, the company has Operating Margin of -32 284.9%.

Back to Top